Avinger, Inc. (AVGR)

Seite 1 von 3
neuester Beitrag: 13.09.20 22:31
eröffnet am: 08.01.18 16:34 von: Chalifmann3 Anzahl Beiträge: 54
neuester Beitrag: 13.09.20 22:31 von: larsuwe Leser gesamt: 10119
davon Heute: 3
bewertet mit 1 Stern

Seite: Zurück 1 | 2 | 3 Weiter  

08.01.18 16:34

21364 Postings, 4919 Tage Chalifmann3Avinger, Inc. (AVGR)

Avinger Announces Treatment of First Patients Globally With Next Generation Pantheris

REDWOOD CITY, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that Arne Schwindt, M.D., a vascular surgeon at St. Franziskus Hospital in Münster, Germany, has successfully treated the first seven patients with the next generation Pantheris Lumivascular atherectomy system. Dr. Schwindt, an experienced operator of Lumivascular technology, used the next generation Pantheris to treat seven separate patients with a variety of lesion types, including in-stent restenosis (ISR), a calcified lesion, and a chronic total occlusion, in arteries above and below the knee.

The next generation Pantheris design includes a simplified single balloon system for both apposition of the device and occlusion of blood flow, a stiffer shaft for increased pushability, a more robust nose cone with the option for more tissue storage capacity, and an enhanced cutter design. This device is available in limited supply for commercial sale in the EU; it is not available commercially in the United States at this time.

In each of the seven cases, Pantheris performed as intended, and Dr. Schwindt made note of the design features that enabled significant performance improvements as compared to previous versions of the device, including better directional control of the cutter blade for more precise atherectomy. Dr. Schwindt also provided feedback about the increased maneuverability of the system, greater tissue capture versus the similarly sized previous version of Pantheris, increased efficiency and ease of cleaning the device between insertions, and high quality imaging in a variety of vessel diameters.

In commenting on his initial cases, which included a patient with a total occlusion of a stent and multiple below-the-knee lesions, Dr. Schwindt noted, ?Next generation Pantheris with real-time image guidance enabled me to see the stent struts and precisely target and remove substantial amounts of tissue that had grown into the stent. In two patients the disease extended below the knee. Image-guided atherectomy with the next generation Pantheris made it possible to precisely target and remove atherosclerotic plaque in this region while conserving the deep wall components and thus reducing the risk of perforations in these small vessels. The angiographic outcome was excellent.?

?We are thrilled that Dr. Schwindt was the first in the world to use the next generation of Pantheris, especially given the excellent outcomes for patients in this initial experience with the device,? said Jeff Soinski, Avinger?s president and CEO. ?These cases helped to validate the enhancements we have made to Pantheris, both in terms of performance and reliability. We believe the initial results generated by Dr. Schwindt with the device represent an important step both for Avinger and for the evolution of treatment for patients with PAD.?

Atherectomy is a minimally invasive treatment for PAD in which a catheter-based device is used to remove plaque from a blood vessel. Lumivascular technology allows physicians, for the first time ever, to see from inside the artery during an atherectomy procedure by using an imaging modality called optical coherence tomography, or OCT, that is displayed on Avinger?s proprietary Lightbox console. Physicians performing atherectomy with other devices must rely solely on X-ray as well as tactile feedback to guide their interventions while treating complicated arterial disease. With the Lumivascular approach, physicians can more accurately navigate their devices and treat PAD lesions, thanks to the real-time OCT images generated from inside the artery, without exposing healthcare workers and patients to the negative effects of ionizing radiation.

About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the PantherisÒ family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.  
Seite: Zurück 1 | 2 | 3 Weiter  
28 Postings ausgeblendet.

23.05.18 15:12

825 Postings, 935 Tage macSteve0702Comeback

Durch die FDA Akzeptanz kommt hier wieder Leben rein. http://investors.avinger.com/...ml?c=253894&p=irol-news&nyo=0

Die rechtlichen Streitereien (5 Mio Dollar) scheint man auch beigelegt zu haben.

Mal sehen was die kommenden Wochen/Monate bringt.  

23.05.18 15:16

3812 Postings, 2381 Tage Nobsy11Aktienanzahl 0,880 Mio. (Stand: 12.02.18)

short squeeze  ;-)  

23.05.18 18:34

3288 Postings, 3010 Tage phineasAktienanzahl

Yahoo nennt eine Aktienanzahl von 4,84 Mio.


An der Nasdaq sind bis jetzt 14,65 Mio. Siück gehandelt worden.
Wie dem auch sei, das kann hier noch eine sehr interessante Story werden.  

23.05.18 19:36

3617 Postings, 3125 Tage Monaco1Überlege noch den Einstieg

Welche KZ habt ihr so?  

24.05.18 09:49

3812 Postings, 2381 Tage Nobsy11...selbst nachbörslich..

nicht weit vom Tageshoch...

Ich denke heute geht es weiter hoch und zum WE evtl eine leichte Konsolidierung...bleibt auf jeden Fall sehr spannend - good luck  

24.05.18 10:03

4565 Postings, 2438 Tage Cobra7hmmh

das sieht nach conversion der convertibles aus, bei ca. 5.5M Shares, kommt die nicht wirklich so hoch ;-)

siehe 10-Q Sharezahl

bald noch mehr Shares aufm Markt, aber ihr macht das schon hier


24.05.18 10:10

4565 Postings, 2438 Tage Cobra7....

The Series B preferred stock issued in the public offering is convertible into shares of the company’s common stock at a conversion price of $2.00 per share. Each share of Series B preferred stock will be accompanied by (a) a Series 1 warrant, which expires on the earlier of (i) 60 days following the clearance by the FDA of a new lower-profile version of the company’s Pantheris atherectomy system and (ii) the seventh anniversary of the warrant’s issuance, to purchase 500 shares of the company’s common stock at an exercise price of $2.00 per share, and (b) a Series 2 warrant, which expires on the seventh anniversary of its issuance, to purchase 500 shares of the company’s common stock at an exercise price of $2.00 per share.


24.05.18 10:29

3617 Postings, 3125 Tage Monaco1dabei mit KZ 5$

24.05.18 10:38

3812 Postings, 2381 Tage Nobsy11hat sich schon jemand...

mit sagenhaften 50 shares im Premarket bedient - der/die kann es gar nicht abwarten  :-))


24.05.18 11:08

4565 Postings, 2438 Tage Cobra7naja

da kann man froh sein, wenn diese erstmal gesperrt sind

, aber die Bs nicht... mal schauen ob deine 5 kommen

On February 14, 2018, the Company entered into a Series A Purchase Agreement with CRG, pursuant to which it agreed to convert $38,000,000 of the outstanding principal amount of its senior secured term loan (plus $3,800,000 in back-end fees and


Table of Contents

prepayment premium applicable thereto), totaling $41,800,000, into a newly authorized Series A preferred stock.  The Series A preferred stock is initially convertible into 20,900,000 shares of common stock subject to certain limitations contained in the Series A Purchase Agreement.  Under the terms of the Series A Purchase Agreement, the holders of Series A preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series A preferred stock or cash, at the Company’s option. The shares of Series A preferred stock have no voting rights and rank senior to all other classes and series of the Company’s equity in terms of repayment and certain other rights. The Series A preferred stock and any of the Company’s common stock issued upon conversion of the Series A preferred stock are subject to a lockup agreement through February 14, 2019.


24.05.18 11:45

3812 Postings, 2381 Tage Nobsy11...lesenswerter Artikel zu der

Kernkompetenz von AVGR...

Hier wird nochmals deutlich, welche Bedeutung das nunmehr verbesserte und durch die FDA freigegebene Produkt hat - ein Weltmarkt - viel Spaß beim Lesen..  

30.10.18 12:13

3617 Postings, 3125 Tage Monaco1Warum der Kursverfall?

Finde keine Information. Kann jemand helfen?


30.10.18 13:56

12444 Postings, 3511 Tage RudiniKapitalerhöhung zu 0,40 USD

06.11.18 20:31

3617 Postings, 3125 Tage Monaco1Jetzt

Ein paar Stücke ins Depot gelegt  

11.11.18 19:09

3617 Postings, 3125 Tage Monaco1Jemand ne Ahnungg wo die Reise hingehen könnte?

29.11.18 18:04

2404 Postings, 1233 Tage franzelsepnoch ist keine "deficiency notice"

von der SEC raus ... kann aber nicht mehr lange dauern. Meinungen?  

19.12.18 20:35

3617 Postings, 3125 Tage Monaco1Ist hier noch jemand mit an Board?

13.05.19 10:50

330 Postings, 4720 Tage oktayKlop Klop klop

Einer mal zu Hause oder alle im tiefschlaf  

12.07.19 20:34

330 Postings, 4720 Tage oktayHaaaalllloooooo

Ist hier jemand dabei  

25.07.19 01:54

330 Postings, 4720 Tage oktayGlaub hier ist keiner

Ist besser so, dann lese ich meine Meinungen selbst,

Anstehende Termine für AVINGER INC
  12.08.19§ Erstes Halbjahr 2019 Ergebnisveröffentlichung (geplant)
  11.11.19§ Q3 2019 Ergebnisveröffentlichung (geplant)
  04.03.20§ Jahr 2019 Ergebnisveröffentlichung (geplant)  

29.07.19 02:08

330 Postings, 4720 Tage oktayAvinger ist fast das fast

Das gleiche wie Microbot medical, brauch nur etwas Zeit damit das Obst reif wird. Abwarten und Geduld ist die Schlüssel Wort für diesen aktie.  

09.08.19 01:20

330 Postings, 4720 Tage oktayErst ab 01.09 wird hier spannend

29.10.19 14:41

330 Postings, 4720 Tage oktayHaaaallllooooo

Ist jemand noch hier  

13.09.20 22:31

681 Postings, 5327 Tage larsuweZulassung am Fr erhalten.Rebound am Mo

Seite: Zurück 1 | 2 | 3 Weiter  
   Antwort einfügen - nach oben